InflaRx N.V. (NASDAQ:IFRX) Receives $6.17 Consensus PT from Analysts

InflaRx N.V. (NASDAQ:IFRX) has been assigned a consensus recommendation of “Moderate Buy” from the seven brokerages that are currently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and five have given a buy recommendation to the company. The average 12 month price target among analysts that have covered the stock in the last year is $6.1667.

Several equities analysts recently weighed in on the company. HC Wainwright reissued a “buy” rating and set a $6.00 price objective on shares of InflaRx in a research report on Tuesday, December 30th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of InflaRx in a research report on Monday, December 29th. Guggenheim cut their price target on InflaRx from $22.00 to $14.00 and set a “buy” rating for the company in a report on Friday, March 20th. Leerink Partners restated a “market perform” rating and issued a $2.00 price objective (down from $5.00) on shares of InflaRx in a research note on Wednesday, December 3rd. Finally, Raymond James Financial reaffirmed an “outperform” rating on shares of InflaRx in a research report on Wednesday, December 31st.

Institutional Investors Weigh In On InflaRx

Several hedge funds have recently made changes to their positions in the stock. Cubist Systematic Strategies LLC raised its stake in shares of InflaRx by 33.9% in the first quarter. Cubist Systematic Strategies LLC now owns 30,053 shares of the company’s stock valued at $31,000 after purchasing an additional 7,616 shares in the last quarter. HRT Financial LP bought a new stake in InflaRx in the 4th quarter valued at $47,000. Concurrent Investment Advisors LLC raised its stake in shares of InflaRx by 56.9% in the 4th quarter. Concurrent Investment Advisors LLC now owns 52,951 shares of the company’s stock valued at $53,000 after buying an additional 19,200 shares in the last quarter. Insigneo Advisory Services LLC acquired a new position in shares of InflaRx in the 4th quarter valued at $61,000. Finally, Quadrature Capital Ltd bought a new position in shares of InflaRx during the 4th quarter worth about $104,000. Institutional investors own 42.39% of the company’s stock.

InflaRx Stock Performance

NASDAQ IFRX opened at $0.91 on Friday. InflaRx has a 1 year low of $0.71 and a 1 year high of $1.94. The company has a fifty day simple moving average of $0.92 and a 200 day simple moving average of $1.12. The company has a market cap of $65.92 million, a P/E ratio of -1.20 and a beta of 1.48.

InflaRx (NASDAQ:IFRX) last announced its earnings results on Friday, March 20th. The company reported ($0.17) EPS for the quarter, hitting the consensus estimate of ($0.17). The firm had revenue of ($0.04) million during the quarter, compared to the consensus estimate of $0.03 million. Equities research analysts forecast that InflaRx will post -1.04 EPS for the current fiscal year.

About InflaRx

InflaRx N.V. is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement‐1a (C5a) pathway. The company’s lead product candidate, vilobelimab (IFX‐1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro‐inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high‐unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.

Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.